Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421954 · ClinicalTrials.gov registry record · Phase 3
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
A Phase 3 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT00421954 is a Phase 3 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants.
The verdict
NCT00421954, a Phase 3 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon® for 7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically appropriate, they may also stay at the New York State Psychiatric Institute (NYSPI) Schizophrenia Research Unit (SRU) inpatient facility.
Interventions
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421954
The ClinicalTrials.gov registry entry for NCT00421954 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ziprasidone is the first listed.
NCT00421954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00421954 about?
NCT00421954 is a clinical study titled "Open-label Ziprasidone Study for Psychosis Treatment in Adolescents". This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon® for 7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically appropriate, they may also ...
What is the current status of trial NCT00421954?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2006-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00421954?
The interventions under investigation include: Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00421954?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.